The importance of lifestyle intervention trials in cancer survivors
Results of ASCEND-4 trial of ceritinib versus chemotherapy in ALK+ NSCLC patients
Gilberto De Castro Jr
Is lorlatinib a better option for NSCLC?
The nurse's perspective on caring for lung cancer patients receiving immunotherapy
Differences in expression of predictive biomarkers between primary and metastatic NSCLC